



**Item 8.01 Other Events**

Agenus Inc. today announced that GlaxoSmithKline's ("GSK") MAGRIK study, a Phase 3 randomized, blinded, placebo-controlled MAGE-A3<sup>ii</sup> cancer immunotherapeutic trial in non-small cell lung cancer (NSCLC) patients, which contains Agenus' QS-21 Stimulon<sup>®</sup> adjuvant, will be stopped. GSK announced that it will not be possible to identify a sub-population of gene-signature positive NSCLC patients that may benefit from the treatment.

i A double-blind, randomised, placebo-controlled Phase III trial to assess the efficacy of recMAGE-A3 + AS15 antigen-specific cancer immunotherapeutic as adjuvant therapy in patients with MAGE-A3 positive NSCLC (MAGRIT, NCT00480025).

ii MAGE-A3 cancer immunotherapeutic consists of recombinant MAGE-A3 protein and a novel immunostimulant AS15 (a combination of QS-21 Stimulon<sup>®</sup> adjuvant, monophosphoryl lipid A, and CpG7909, a TLR-9 agonist, in a liposomal formulation).

**Item 9.01 Financial Statements and Exhibits**

(d) Exhibits

The following exhibit is filed herewith:

99.1 Press Release dated April 2, 2014

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**AGENUS INC.**

Date: April 2, 2014 By: /s/ Garo H. Armen

Garo H. Armen  
Chief Executive Officer

---

EXHIBIT INDEX

| <u>Exhibit No.</u> | <u>Description of Exhibit</u>     |
|--------------------|-----------------------------------|
| 99.1               | Press Release dated April 2, 2014 |